Should You Buy Eli Lilly Stock Now or Wait for a Dip?

Eli Lilly stock has surged over 400% in five years and reached a $1 trillion market cap, driven by its GLP-1 weight loss drugs Mounjaro and Zepbound. While the stock trades at a premium valuation of 40x trailing earnings, the company's strong earnings growth, strategic acquisitions in RNA therapies and infectious diseases, and long-term growth prospects make it a compelling buy for long-term investors willing to hold for 5+ years, despite potential short-term volatility.